Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

Head and Neck Cancers, Version 1.2015.

Author information

1
From Memorial Sloan Kettering Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Duke Cancer Institute; Yale Cancer Center/Smilow Cancer Hospital; Massachusetts General Hospital Cancer Center; Moffitt Cancer Center; Vanderbilt-Ingram Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Mayo Clinic Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Roswell Park Cancer Institute; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fox Chase Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; and National Comprehensive Cancer Network.

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

PMID:
26150579
PMCID:
PMC4976490
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center